Gerostate AlphaDeveloping novel therapeutics for aging and chronic disease

GeroState Alpha: Pioneering Longevity

Introduction

GeroState Alpha is a cutting-edge pharmaceutical company dedicated to treating aging and age-related diseases. Incubating at the Buck Institute for Research on Aging, we develop breakthrough pharmaceuticals through proprietary innovations to mitigate and reduce the effects of aging.

Key Features

• Innovative Pharmaceuticals: Developing drugs to treat and slow down aging.
• Proprietary Innovations: Utilizing unique methods to combat age-related diseases.
• Expert Team: Over 50 years of combined experience in aging research.
• Research-Driven: Incubated at the renowned Buck Institute for Research on Aging.
• Mission-Focused: Aiming to increase health span, wellness, and extend lifespan.

Use Cases

• Age-Related Disease Treatment: Targeting diseases that predominantly affect the elderly.
• Health Span Extension: Improving the quality of life by extending the period of good health.
• Lifespan Extension: Pushing the boundaries of human longevity through scientific innovation.
• Pharmaceutical Development: Creating new drugs based on cutting-edge research in aging.

Pricing

Pricing details for our pharmaceuticals and services are available upon request. Contact us directly to learn more about our offerings and how they can benefit you or your organization.

Teams

GeroState Alpha is powered by a passionate team of scientists and industry experts:

• Simon Melov, PH.D/ Founder, CEO: Professor at the Buck Institute with expertise in slowing aging and improving health span.
• Gordon Lithgow, PH.D/ Founder: Chief Academic Officer at the Buck Institute, specializing in small molecules to extend lifespan.
• Mark Lucanic, PH.D/ Founder, CTO: Expert in small molecule and genetic screens, with significant experience in high throughput technologies.
• Edward O. Lanphier II/ Executive Chair: Over 30 years in the biotech industry, former CEO of Sangamo Therapeutics, and pioneer in genome editing.

Our institutional investors include Y Combinator and CRCM Ventures.

For more information, contact:

• Simon Melov: [email protected]
• Gordon Lithgow: [email protected]
• Mark Lucanic: [email protected]